ATR and cancer: Moreover, ATRi and CHK1i are shown to resensitize PARPi-resistant, BRCA1-deficient cancer cells to PARPi [139,140,141,142,143] that also makes ATR-CHK1 pathway an attractive target in drug resistance context.